Novartis Sees Good Clinical Results for Tumour Treatment Sandostatin

1 October 2009 (Last Updated October 1st, 2009 18:30)

Novartis has published new clinical data showing that the risk of disease progression for patients with advanced neuroendocrine tumours (NET) of the midgut was significantly reduced after treatment with Sandostatin. Data from the Phase III Promid study showed a 66% reduction in risk of

Novartis has published new clinical data showing that the risk of disease progression for patients with advanced neuroendocrine tumours (NET) of the midgut was significantly reduced after treatment with Sandostatin.

Data from the Phase III Promid study showed a 66% reduction in risk of disease progression in patients treated with Sandostatin LAR Depot (octreotide acetate for injectable suspension) versus placebo.

In the study, patients receiving the treatment more than doubled their time without tumour progression for a median of 14 months compared with a median of six months for those who received placebo.

Trial lead investigator Rudolf Arnold said that these are promising data for patients with NET who face limited treatment options.

"Promid is a placebo-controlled randomised trial that showed octreotide LAR can control tumour growth in all patients with NET of the midgut whether or not they experience symptoms," Arnold said.

LAR is indicated to treat the diarrhoea and flushing episodes associated with advanced carcinoid tumours.